(Q45363548)

13 December 2017

title

Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations (English)

1 reference

cost-effectiveness analysis

13 December 2017

main subject

1 reference

1 reference

1 reference

7

1 reference

13 December 2017

Peter Vickerman

2

0 references

Sharon J Hutchinson

5

object named as

Sharon J Hutchinson

1 reference

13 December 2017

Natasha K Martin

1

1 reference

13 December 2017

Alec Miners

3

1 reference

13 December 2017

Graham R Foster

4

1 reference

13 December 2017

David J Goldberg

6

1 reference

13 December 2017

language of work or name

English

0 references

publication date

6 December 2011

1 reference

13 December 2017

1 reference

13 December 2017

volume

55

1 reference

13 December 2017

issue

1

1 reference

13 December 2017

page(s)

49-57

1 reference

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

13 December 2017

cites work

1 reference

An evidence synthesis approach to estimating Hepatitis C prevalence in England and Wales.

21 January 2018

1 reference

Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis.

21 January 2018

1 reference

Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users

21 January 2018

1 reference

The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.

21 January 2018

1 reference

Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews

21 January 2018

1 reference

Hepatitis C Infection Among Injecting Drug Users in England and Wales (1992-2006): There and Back Again?

21 January 2018

1 reference

Mathematical modelling of hepatitis C treatment for injecting drug users

21 January 2018

1 reference

Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

21 January 2018

1 reference

Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.

21 January 2018

1 reference

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.

21 January 2018

1 reference

Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

21 January 2018

1 reference

Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy?

21 January 2018

1 reference

Hepatitis C treatment for injection drug users: a review of the available evidence

21 January 2018

1 reference

Follow-up studies of treatment for hepatitis C virus infection among injection drug users

21 January 2018

1 reference

Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

21 January 2018

1 reference

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation

21 January 2018

1 reference

Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.

21 January 2018

1 reference

Estimating the prevalence of ex-injecting drug use in the population.

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin

21 January 2018

1 reference

Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection

21 January 2018

1 reference

The self-reported personal wellbeing of a sample of Australian injecting drug users.

21 January 2018

1 reference

Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment

21 January 2018

1 reference

Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study.

21 January 2018

1 reference

Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies

21 January 2018

1 reference

Incidence of heroin use in Zurich, Switzerland: a treatment case register analysis.

21 January 2018

1 reference

Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.24656

1 reference

release_kd77utbzr5gljg7cf4pjxjvaxq

13 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kd77utbzr5gljg7cf4pjxjvaxq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference